The clinical feasibility, safety, and potential effectiveness of combining PDK1 inhibitors in anti-PD1/PDL1-based drug therapy in BCs deserve further verification, which might lead to breakthroughs in BC treatment. The gene discussed is CD274; the disease is breast cancer.